Andreas Bugge Tinggaard

VIP, Assistant Professor

Aarhus University
Country flagDenmark

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Introduction: Patients with prostate cancer are at increased risk of cardiovascular events. A non-electrocardiogram gated CT scan of the thorax is part of the diagnostic workup, allowing for assessment of coronary calcifications. However, the prognostic impact of a coronary artery calcium score (CACS) obtained from such CT scans is uncertain. This study aimed to investigate the association between CACS and a combined endpoint of all-cause death, myocardial infarction, or stroke in patients with recently diagnosed prostate cancer. Methods: The primary analysis included patients (N = 571) with recently diagnosed prostate cancer and without known coronary artery disease undergoing prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT). Patients were stratified into four CACS groups. Cox proportional hazard models adjusted for risk factors were used to examine the association between CACS and the combined endpoint. Results: Patients were distributed in the four CACS groups as follows: CACS 0–10 (26%), 11–99 (21%), 100–399 (24%), and ≥400 (29%). An increased risk of the combined endpoint was found with increasing CACS. Compared with CACS 0–10, the hazard ratios for CACS 11–99, 100–399 and ≥400 were 0.95 (95% confidence interval [CI]: 0.37–2.42), 2.39 (95% CI: 1.13–5.09) and 3.14 (95% CI: 1.52–6.48), respectively. Only 53% of patients in the CACS ≥400 group received statins. Conclusion: In patients with prostate cancer, assessment of a CACS from the initial PET/CT scan allows for the identification of patients with a threefold higher risk of death, myocardial infarction, or stroke. Initiation of preventive statin treatment in these patients could reduce cardiovascular events.

Year:

2025

Aims Despite the high risk of rehospitalization for heart failure (HF) and death among patients admitted to the intensive cardiac care unit (ICCU), no accurate prediction score for these outcomes exists. We aimed to develop a risk score to predict unplanned HF hospitalization and death 1-year post-discharge in an unselected cohort of patients admitted to the ICCU. Methods Based on a national, multicentre study, we included all consecutive patients admitted to the ICCUs in 39 French centres from 7 to 22 April 2021. We randomly selected a training cohort of 21 centres (n = 1008) to develop the ICCU-HF score and a validation cohort of eight other centres (n = 463). The primary composite outcome was unplanned hospitalization for HF and cardiovascular death at 1-year follow-up after discharge. Using the score, patients were stratified into three risk groups to evaluate the prognostic value. Results Using a least absolute shrinkage and selection operator (LASSO) regression approach, we identified seven predictors: left ventricular ejection fraction, significant valvular disease grade 2+, Killip score >1, NT-proBNP, creatinine level, previous ventricular arrhythmia and use of inotropes during hospitalization. In 1471 patients (63 ± 15 years, 70% men), 99 (6.7%) experienced the primary outcome. The ICCU-HF score outperformed NT-proBNP, the strongest individual predictor (area under the curve [AUC] 0.77, 95% CI [0.71–0.83] vs. AUC 0.72, 95% CI [0.66–0.79], P = 0.008), demonstrating excellent performance with an AUC of 0.83 (95% CI: 0.77–0.89) to predict outcomes in the validation cohort. Compared with the low-risk group, the intermediate-risk and high-risk groups had significantly higher risks of the composite outcome (HR 4.09, 95% CI [2.23–7.50], P < 0.001 and 12.69, 95% CI [7.02–22.95], P < 0.001), proving strong risk stratification capability of the ICCU-HF score. Conclusions The ICCU-HF score showed good performance in predicting the 1-year risk of unplanned HF hospitalization and death in a large cohort of unselected patients admitted to the ICCU, with excellent results in the validation cohort. This score effectively stratifies patients into risk groups, enhancing its utility in clinical decision-making.

Year:

2025

Background Skeletal muscle wasting is critical in patients with heart failure (HF). Whereas prior studies have employed appendicular lean mass (ALM) normalized by height squared to identify low skeletal muscle mass, the potential of ALM normalized to body mass index (ALM/BMI) remains unexplored in patients with HF. In this study, we compared the use of 2 skeletal muscle mass indices in patients with HF to examine their sex‐specific correlations with measures of physical capacity, quality of life, and daily physical activity. Methods and Results A total of 111 patients with HF underwent dual x‐ray absorptiometry, physical capacity tests, and accelerometry and answered a quality‐of‐life questionnaire. ALM normalized by height squared and ALM/BMI indices disagreed in classifying low muscle mass (Cohen's κ, −0.008 [95% CI, −0.094 to 0.177]; P =0.93). ALM/BMI correlated well with 6‐minute walking distance in women and men ( R =0.67 and 0.49; P <0.001), with maximal oxygen uptake in women and men ( R =0.41 and 0.48; P <0.05), and with maximal muscle strength in women and men ( R =0.54 and 0.43; P <0.01). Inversely, ALM normalized by height squared did not correlate significantly with 6‐minute walking distance or maximal oxygen uptake and correlated with maximal muscle strength only in men ( R =0.43; P <0.001). Only ALM/BMI allowed for identification of a low‐muscle‐mass group characterized by poor quality of life (Minnesota Living With Heart Failure Questionnaire score of 33±21 versus 25±16; P =0.027) and less daily time spent in moderate to vigorous physical activity (8 [3–17] versus 15 [9–37] minutes; P <0.001). Conclusions ALM/BMI was superior for identifying clinically significant muscle dysfunction in both female and male patients with HF.

Year:

2024

Background Physical activity (PA) measured by accelerometry is proposed as a novel trial endpoint for heart failure (HF). However, standardised methods and associations with established markers are lacking. This study aimed to examine PA measurements and accelerometer repeatability in patients with HF and age- and sex-matched controls, and study correlations with established prognostic HF markers, body composition, and quality of life (QoL). Methods Accelerometry was performed in 105 patients with HF with left ventricular ejection fraction (LVEF) ≤ 40% and in 46 controls. Participants also underwent dual X-ray absorptiometry, cardiopulmonary exercise testing, a six-minute walking test (6MWT), echocardiography, and NT-proBNP measurement, and completed a QoL questionnaire. Results Average acceleration was markedly reduced in patients with HF compared with healthy controls (16.1 ± 4.8 mg vs 27.2 ± 8.5 mg, p < 0.001). Healthy controls spent a median daily 56 min (IQR 41–96 min) in moderate-to-vigorous PA (MVPA), whereas HF patients spent only 12 min (IQR 6–24) in MVPA. In HF patients, average acceleration correlated moderately with 6MWT ( R = 0.41, p < 0.001) and maximal oxygen uptake (peak V O 2 ) ( R = 0.36, p < 0.001) but not with NT-proBNP, LVEF, or QoL. Patients in NYHA class II showed a higher average acceleration than patients in NYHA III (16.6 ± 4.9 mg vs 14.0 ± 3.6 mg, p = 0.01). Conclusions Daily PA was severely reduced in patients with HF compared with healthy controls. In HF patients, we found moderate correlations of accelerometer measurements with markers of physical capacity but not with LVEF or NT-proBNP. Trial registration NCT05063955. Registered 01 June 2021—retrospectively registered. Graphical abstract

Year:

2024

Collaborators (17)

Mogens Johannsen

VIP, Professor

Aarhus University

DENMARK
View details

Niels Moller

VIP, Professor

Aarhus University

DENMARK
View details

Johannes Grand

Medical doctor

Bispebjerg Hospital

DENMARK
View details

Janne Kærgård Mortensen

VIP, Clinical Associate Professor

Aarhus University

DENMARK
View details

Niels Jessen

Head of Research

Aarhus University

DENMARK
View details

Paul Christian Schulze

Professor and Chair

Jena University Hospital

GERMANY
View details

Henrik Wiggers

Consultant, Professor, MD, PhD, DMSc

Aarhus Universitetshospital

DENMARK
View details

Simon Winther

VIP, Clinical Professor

Aarhus University

DENMARK
View details

Lotte Sørensen

DVIP-part-time lecturer, Part-time Lecturer

Aarhus University

DENMARK
View details

Roni Nielsen

VIP, Clinical Associate Professor

Aarhus University

DENMARK
View details

Kristian Vissing

Aarhus University

DENMARK
View details

Fulvio Reggiori

VIP, Professor

Aarhus University

DENMARK
View details

Charlotte Lock Rud

Aarhus University

DENMARK
View details

Morten Bøttcher

VIP, Clinical Professor

Aarhus University

DENMARK
View details

Anders Hostrup Larsen

Aarhus University

DENMARK
View details

Joern Dengjel

Professor for Biochemistry and Cell Biology

University of Fribourg

SWITZERLAND
View details

Christian Lodberg Hvas

VIP, Clinical Professor

Aarhus University Hospital

DENMARK
View details